Summary
The response claims multiple cost/price drivers and assistance-program details that are not supported by the provided FDA prescribing information excerpts, which focus on indications, dosing, safety, interactions, and use in populations.
Category Scores
Accurate Statements
Exemestane is an aromatase inhibitor used in hormone-receptor–positive breast cancer.
Supported insofar as labeling describes AROMASIN (exemestane) as indicated for estrogen-receptor positive early breast cancer in postmenopausal women (Indications and Usage 1.1) and mechanism as aromatase inactivator (12.1). Advanced breast cancer indication is also present (1.2).
Unsupported Statements
The out-of-pocket cost of exemestane varies based on whether the patient is paying for a brand versus a generic.
No pricing/out-of-pocket cost or brand-vs-generic cost statements are present in the provided prescribing information excerpts.
The out-of-pocket cost of exemestane varies based on dose and insurance or pharmacy discount arrangement.
No pricing, out-of-pocket cost, dose-cost relationship, insurance coverage, or discount arrangement statements are present in the provided excerpts.
Key drivers of exemestane price include generic availability and which manufacturer is received.
No information about pricing drivers, manufacturer selection, or generic availability impact is present in the provided excerpts.
Key drivers of exemestane price include dose strength (tablets) and daily pill count.
No cost drivers related to dose strength or pill count are present in the provided excerpts.
Key drivers of exemestane price include insurance tier/copay rules or whether the patient is self-paying.
No insurance tier/copay or self-pay pricing information is present in the provided excerpts.
Key drivers of exemestane price include pharmacy location and negotiated pricing.
No pharmacy location or negotiated pricing statements are present in the provided excerpts.
Pricing for exemestane is usually lowest when a generic version is available and stocked by the pharmacy.
No general/typical pricing comparisons or statements about lowest price conditions are present in the provided excerpts.
Brand pricing tends to be materially higher than generic pricing for exemestane.
No pricing comparison statements between brand and generic are present in the provided excerpts.
DrugPatentWatch.com tracks drug patent/exclusivity information and can help understand whether pricing pressure from generic entry may apply.
No mention of DrugPatentWatch.com, patent-tracking services, or pricing pressure from generic entry is present in the provided excerpts.
Copay cards or patient assistance programs may exist for exemestane depending on the current manufacturer and the patient’s eligibility.
No copay cards, patient assistance programs, or manufacturer/eligibility-based assistance statements are present in the provided excerpts.
Contradictions
Important Omissions
If the intent was to provide FDA-label-relevant practical dosing/safety guidance, the response omitted label specifics such as the recommended dose (25 mg once daily after a meal) and administration constraints (e.g., not coadministered with systemic estrogen-containing agents).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The unsupported claims primarily concern cost/market factors and external tracking/assistance programs. No direct contraindications, dosing, or safety warnings were stated incorrectly, but the inclusion of substantial unsupported non-label content reduces label alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are about out-of-pocket pricing, pharmacy/insurance discount mechanisms, and external websites/copay programs, none of which are supported by the provided FDA prescribing information excerpts.
Suggested Improvement
Limit claims to what is present in the FDA label excerpts (indications, recommended dosing, contraindications, warnings/precautions, drug interactions, and specific populations). Remove or qualify all cost/price-driver and assistance-program assertions unless supported by label content (which it is not in the provided excerpts).